TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00257608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib HCl
Description: Oral repeating dose
Study: NCT02555774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: cognitive training is held 2 times a week for 3 months, 90 minutes per 1 session. It includes cognitive exercise of multiple cognitive domains such as memory, attention, calculation, executive function and visuospatial function.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification
Description: education about lifestyle modification is done by investigators at the first day of the trial and the investigators conduct weekly phone call to participants to educate the lifestyle modifications

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle modification
Description: education about lifestyle modification is done by investigators at the first day of the trial and the investigators conduct weekly phone call to participants to educate the lifestyle modifications
Study: NCT01570556

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic treatment
Description: In patients with positive urinary culture, seven days of antibiotics will be given orally according to the bacteriogram sensitivity.
Study: NCT00683085

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*02:01-restricted VEGFR1-derived peptide vaccination
Description: VEGFR1-derived HLA-A\*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m\^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the feasibility and efficacy of this type of peptide.
Study: NCT02876627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: twelve-week aerobic exercise training program consisted of three sessions per week, each session lasting 30 to 60 minutes 50 to 75 percent of their maximum heart rate reserve
Study: NCT01892865

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scheduling using historical means
Description: Scheduling will be performed taking into account historical means only for anesthetic, operative, and turn around time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduling using regression modeling system
Description: A regression model that uses predictor of operative length will be used to predict operative, anesthetic, and turn around time length
Study: NCT03140228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Gel
Description: I-gel is the single use supraglottic airway from intersurgical, UK (Intersurgical Ltd, Wokingham, Berkshire, UK) with an anatomically designed mask made of a gel like thermoplastic elastomer to fit over perilaryngeal and hypopharyngeal structures. It is designed to separate the gastrointestinal and respiratory tracts and also allow a gastric tube to be passed into the stomach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA
Description: The AmbuAuraOnce (Ambu A/S, Ballerup, Denmark) is a supraglottic airway device with an inflatable cuff. It is a disposable device as well, but unlike I-gel, it does not feature a gastric channel.
Study: NCT02213523

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant concentrate A
Description: Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant concentrate B
Description: Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant concentrate C
Description: Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant concentrate D
Description: Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
Study: NCT02260440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given at 200 mg every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days.
Study: NCT00398411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: 400 mg p.o. per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet per day p.o.
Study: NCT02883959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Music therapy will be delivered through headphones during nursing procedures (toilet and/or surgical dressings): from initiation up to 30 minutes after the end of procedure.
Study: NCT01937754

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide supplement
Description: Lozenge consisting of beetroot and 75 mg caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same form factor and flavor as test lozenge but contains no active ingredients
Study: NCT00654121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actrapid HM
Description: 56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
Study: NCT01812031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical imaging
Description: After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations.
Study: NCT01483300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lobaplatin
Description: Gemcitabine 1000 mg/m2 d1, 8; Lobaplatin 30mg/m2 d1 q 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Gemcitabine 1000 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1-3 q 3 weeks
Study: NCT04275557

Intervention type: OTHER
Intervention: Blood Sample collection
Description: Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date), 4-6 weeks post-surgery, if applicable, and at the time of follow-up (approximately 1 year and approximately 2 years after baseline).

Intervention type: OTHER
Intervention: Tissue sample collection
Description: At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue, muscle, fat, tissue from site of metastasis, and cyst fluid (if applicable) will be collected.

Intervention type: OTHER
Intervention: Data collection
Description: Participants will be asked to complete questionnaires at baseline and at 1 year and 2 year follow-ups.
Study: NCT03220984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immuncell-LC intravenous infusion using a CIK cell agent
Description: Patients with metastatic colorectal cancer, which is refractory to the 3rd-line chemotherapy are enrolled in this study. Enrolled patients receive a total of 12 times of Immuncell-LC therapy: 8 times in every 1 week and the next 4 times in every 2 weeks. The treatment responses of immuncell-LC are evaluated by radiologic findings (Abdomin-pelvic CT and Chest CT), immune-markers and a selorogic tumor marker (Carcinoembryologic antigen (CEA)) at the 8th week and 17th week. The safety of Immuncell-LC is evaluated by the results of serologic tests, vital signs, ECOG-PS and adverse events. The follow-up period is the 1 year after the enrolled date.
Study: NCT02165709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional sterilization
Study: NCT02664545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BEAR Scaffold
Description: A sponge, or scaffold, which is surgically placed between the torn ligament ends and sutures are used to repair the torn anterior cruciate ligament.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tendon Graft
Description: A graft of tendon (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee)
Study: NCT03275987

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mammography direct mail coupled with a financial incentive
Description: The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mammography direct mail coupled with a financial incentive
Description: The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Group received usual care, and direct mail 15 months after treatment group received intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Group received usual care, and direct mail 15 months after treatment group received intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy direct mail coupled with a financial incentive
Description: The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colonoscopy direct mail coupled with a financial incentive
Description: The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
Study: NCT02041715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKM-100802 for Injection
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT04424433

Intervention type: DRUG
Group type: OTHER
Intervention: Oxygen
Description: Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
Study: NCT04234802

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heat Education and Awareness Tools
Description: HEAT training will be delivered to agricultural workers by research staff in this study in the spring. HEAT training uses interactive approaches to engage participants and posters with visuals. Training covers types of heat-related illness and treatments, risk factors, appropriate clothing and hydration, and keeping cool in the home and community. The HEAT awareness application was developed in collaboration with Washington State University's AgWeatherNet Program to notify supervisors signed up for the service about hot weather conditions that might increase the risk for adverse health effects for workers. The HEAT awareness application is designed to allow subscribers to select weather stations of interest and view current heat indices as well as maximum daily heat indices forecasted over the following week. This information is coupled with information about health effects and prevention of adverse heat health effects. Materials are provided in English and Spanish.
Study: NCT04166747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality experience
Description: Participants will receive virtual reality based experience and will be assessed for its influence on happiness, functional fitness components and quality of life of older age groups.
Study: NCT01467557

Intervention type: DEVICE
Intervention: narafilcon B daily disposable soft contact lenses
Description: daily disposable soft contact lenses

Intervention type: DEVICE
Intervention: etafilcon A daily disposable soft contact lenses
Description: daily disposable soft contact lenses
Study: NCT00960245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadolol (1 x 80 mg) Tablets (Invamed, Inc)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
Study: NCT02263547

Intervention type: DRUG
Group type: OTHER
Intervention: teriflunomide

Intervention type: DRUG
Group type: OTHER
Intervention: Colestipol
Study: NCT01076699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.075 mg RVX-100
Description: This group is taking the lowest dose of RVX-100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.125 mg RVX-100
Description: This group is taking an average dose of RVX-100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.250 mg RVX-100
Description: This group is taking the highest dose of RVX-100

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: This group is taking a placebo
Study: NCT02738619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 1600 UI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04720807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole combined with anlotinib hydrochloride
Description: Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.
Study: NCT02644304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: 50 mg tablet twice daily from the second day of menses to the sixth day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: 50 mg tablet twice daily from the second day of menses to the sixth day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: Cabergoline 0.25 mg (half tablet) every 3 days (4 doses).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo(half tablet) every 3 days (4 doses).
Study: NCT04199390

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total hip arthroplasty
Description: each patient is expected to undergo an anterior total hip arthroplasty procedure and some sort of physical therapy postoperatively

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total hip arthroplasty
Description: each patient is expected to undergo an anterior total hip arthroplasty procedure and some sort of physical therapy postoperatively
Study: NCT02156947

Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy
Description: The technique used for LC was the conventional four-trocar approach (10-mm optic at the umbilicus, 10-mm trocar in the epigastrium and two 5-mm trocars in the right upper abdomen).

Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy
Description: The technique used for LC was the conventional four-trocar approach (10-mm optic at the umbilicus, 10-mm trocar in the epigastrium and two 5-mm trocars in the right upper abdomen).
Study: NCT04595292

Intervention type: OTHER
Intervention: older adults, assessment
Description: Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
Study: NCT03452345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meditoxin
Description: Meditoxin (Botulinum toxin type A)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Normal saline)
Study: NCT03171948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Almond Group
Description: Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nut Free group
Description: continue their diet without any nut consumption.
Study: NCT03395093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Five minutes before the patients is done the flexible bronchoscopy, fentanyl will be intravenous injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Five minutes before the patients is done the flexible bronchoscopy, midazolam will be intravenous injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Five minutes before the patients is done the flexible bronchoscopy, midazolam will be intravenous injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be intravenous injected as soon as the flexible bronchoscopy begins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be intravenous injected as soon as the flexible bronchoscopy begins.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index monitoring
Description: Bispectral Index monitoring will be used in the process of the flexible bronchoscopy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral Index monitoring
Description: Bispectral Index monitoring will be used in the process of the flexible bronchoscopy.
Study: NCT00088946

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: 4-200mg capsules PO daily for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 100 mg PO daily for 12 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erlotinib placebo
Description: identical to Erlotinib in look and appearance of dosing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib placebo
Description: identical to Erlotinib in look and appearance of dosing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: identical to Polyphenon E in look and appearance of dosing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Polyphenon E
Description: identical to Polyphenon E in look and appearance of dosing.
Study: NCT05326295

Intervention type: DIAGNOSTIC_TEST
Intervention: CTC detection
Description: CTCs separation and enrichment technology. Combined with the prognosis of patients with recurrence and survival time, we explored the evaluation of CTC number, cell phenotype distribution, PDL1 and FOXC2 expression on the prognosis of early stage breast cancer patients. The research results are expected to provide a new effective index and theoretical basis for evaluating the treatment efficacy of breast cancer patients.
Study: NCT02537028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2364447C
Description: Subjects will be administered with MSC2364447C 25 milligrams orally once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2364447C
Description: Subjects will be administered with MSC2364447C 75 milligrams orally once daily for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered with placebo matching to MSC2364447C orally once daily for 4 weeks.
Study: NCT03455127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FSI ECD
Description: Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
Study: NCT04048187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phone Application
Description: Phone application is developed to adjust hearing aids. It incorporates functionalities like volume control and program change.
Study: NCT00251212

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Motivational Interviewing & Skills Training
Description: Single session, 45 minute brief intervention during Emergency Department Visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Motivational Interviewing & Skills Training
Description: Single session, 45 minute brief intervention during Emergency Department Visit
Study: NCT03002363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Modeling Intervention
Description: Prior to arrival of the audiological evaluation, the child and caregiver will be required to watch one of two videos created by the research personnel. One video, the intervention video, is a behavior modeling video walking through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment. The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Video
Description: The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
Study: NCT01173939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: 5 mg/day or 10 mg/day of pravastatin will be administered orally for 36 months, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<120 mg/dL (JASGL 2007 target level) as quickly as possible. (Maximum dose increase of pravastatin: 20 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 5 mg/day or 10 mg/day of rosuvastatin will be administered orally for 36 months based on the LDL-C level of the subject, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<70 mg/dL as quickly as possible. (Maximum dose increase to rosuvastatin: 20 mg/day)
Study: NCT04260711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMT
Description: Discontinuation of patients' own disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)